Oracle stock falls in late trade after SEC filing shows planned sale by executive (ORCL)
29 December 2025
1 min read

Oracle stock falls in late trade after SEC filing shows planned sale by executive (ORCL)

NEW YORK, December 29, 2025, 16:43 ET — After-hours

  • Oracle shares fell 1.3% late Monday as an SEC filing showed a planned sale by an Oracle executive.
  • The stock underperformed several large software peers in a thin, year-end session.
  • Investors remain focused on Oracle’s AI-related spending plans and the next earnings update.

Oracle shares fell 1.3% in after-hours trading on Monday to $195.38, after an SEC filing showed an Oracle executive filed to sell a block of shares.

The disclosure matters because trading has been thin into year-end, when incremental flows can push large-cap software names around. It also keeps attention on insider activity at a time when investors are debating how quickly Oracle’s cloud growth will translate into cash generation.

Oracle has positioned its cloud business as a supplier of computing capacity for artificial intelligence workloads, but that push requires heavy capital expenditures — spending on data centers and equipment — that can pressure free cash flow if demand or pricing slips.

U.S. stocks ended lower on Monday, with the Nasdaq down 0.5% and the S&P 500 off 0.35% as the holiday-shortened week began. “In light volume trading, we’re seeing a reversal of what we saw over the last couple of days,” said Rob Haworth, senior investment strategist at U.S. Bank Wealth Management. Reuters

Oracle lagged several large software peers in the session, while chipmaker Nvidia, a bellwether for AI-linked trade, fell about 1.2%.

The SEC filing was a Form 144, a notice used when an affiliate plans to sell restricted or control securities under Rule 144. A submission dated Dec. 29 showed Mark Hura, an Oracle officer and president of global field operations, filed to sell up to 15,000 Oracle shares, valued at about $3.0 million.

The filing does not guarantee a sale will occur, but it can draw attention because it signals intent to sell and includes the maximum number of shares covered by the notice.

Oracle’s stock has been volatile in December after the company’s latest quarterly update, when investors weighed strong cloud-growth metrics against a step-up in spending. Oracle said in its fiscal second-quarter release that remaining performance obligations — a measure of contracted revenue not yet recognized — stood at $523 billion.

Earlier this month, Oracle also denied a media report that it was delaying OpenAI-related data-center projects, underscoring how closely traders are tracking the company’s AI infrastructure buildout.

Looking ahead, investors will watch for the next earnings timetable and any guidance on capital spending and cloud demand. Oracle’s investor-relations materials indicate its fiscal third-quarter results are expected in mid-March 2026, while the company has also flagged a $0.50 quarterly dividend with a Jan. 9, 2026 record date and a Jan. 23, 2026 payment date.

For the near term, traders are watching whether Oracle holds above Monday’s intraday low near $193 and whether the stock can reclaim the $200 level as markets head into the final sessions of the year.

Stock Market Today

  • Direxion Daily ORCL Bear 1X ETF Hits Oversold Territory at $23.98
    May 14, 2026, 4:48 PM EDT. Shares of Direxion Daily ORCL Bear 1X ETF (ORCS) traded as low as $23.98 on Thursday, entering oversold territory based on a Relative Strength Index (RSI) reading of 29.4, below the 30 threshold signaling oversold conditions. The RSI is a momentum indicator ranging from 0 to 100. For context, the S&P 500's RSI stands at 87.2, indicating strong strength. ORCS's 52-week range spans from $23.80 to $38.55, with the latest trade at $24.66, down about 3.7% for the day. The low RSI may suggest potential buying opportunities as selling pressure could be easing.

Latest articles

Strategy Inc’s Bitcoin Machine Faces a Funding Test as MSTR Stock Jumps

Strategy Inc’s Bitcoin Machine Faces a Funding Test as MSTR Stock Jumps

14 May 2026
Strategy Inc shares rose 5.3% Thursday as bitcoin climbed, but analysts questioned how long the company’s preferred-stock funding can support bitcoin purchases. The board is asking holders to approve semi-monthly dividends on its STRC preferred shares, with a vote set for June 8. Strategy recently bought 535 bitcoin for $43 million, mostly funded by common stock sales. STRC’s $28.3 billion issuance cap could limit future bitcoin buying.
AST SpaceMobile Stock Jumps as AT&T, Verizon and T-Mobile Move to End Dead Zones

AST SpaceMobile Stock Jumps as AT&T, Verizon and T-Mobile Move to End Dead Zones

14 May 2026
AST SpaceMobile shares rose 11.8% to $83.66 after AT&T, T-Mobile, and Verizon agreed in principle to form a joint venture for satellite-based direct-to-device service. The company said it expects to play a central role as carriers seek to extend coverage beyond cell towers. The venture still requires definitive agreements. Competition includes SpaceX, Skylo, and Amazon’s Globalstar partnership.
US Stock Market Today: Dow Retakes 50,000 as AI Rally Sends S&P 500, Nasdaq to Records

US Stock Market Today: Dow Retakes 50,000 as AI Rally Sends S&P 500, Nasdaq to Records

14 May 2026
The Dow Jones closed above 50,000, with the S&P 500 and Nasdaq hitting new highs as Cisco shares surged after raising its AI infrastructure outlook and announcing nearly 4,000 job cuts. Nvidia gained after U.S. approval for Chinese firms to buy its H200 chips. Cerebras Systems soared 89% on its IPO debut. U.S. retail sales rose 0.5% in April; jobless claims increased by 12,000.
AMD stock today: Shares tick higher after hours as year-end tech selling weighs on chipmakers
Previous Story

AMD stock today: Shares tick higher after hours as year-end tech selling weighs on chipmakers

Eli Lilly stock today: LLY inches up as weight-loss pill pricing, insider filing keep spotlight on obesity drugs
Next Story

Eli Lilly stock today: LLY inches up as weight-loss pill pricing, insider filing keep spotlight on obesity drugs

Go toTop